Water → 8-(4-fluorophenyl)-8-methoxy-2-{(E)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]vinyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine

HRID 2235745ノート

反応式

HRID 2235745 の反応式
Cl.Cl[CH2:3][CH2:4][CH2:5][C:6]([C:13]1[CH:18]=[CH:17][C:16]([F:19])=[CH:15][CH:14]=1)([O:11][CH3:12])[C:7]([NH:9][NH2:10])=O.Cl.Cl.[CH3:22][O:23][C:24]1[CH:25]=[C:26](/[CH:36]=[CH:37]/[C:38](=[NH:42])OCC)[CH:27]=[CH:28][C:29]=1[N:30]1[CH:34]=[C:33]([CH3:35])[N:32]=[CH:31]1.C(OCC)(=O)C.O>C(O)C>[F:19][C:16]1[CH:17]=[CH:18][C:13]([C:6]2([O:11][CH3:12])[CH2:5][CH2:4][CH2:3][N:9]3[N:10]=[C:38](/[CH:37]=[CH:36]/[C:26]4[CH:27]=[CH:28][C:29]([N:30]5[CH:34]=[C:33]([CH3:35])[N:32]=[CH:31]5)=[C:24]([O:23][CH3:22])[CH:25]=4)[N:42]=[C:7]23)=[CH:14][CH:15]=1

参加物

6

反応物 4

HCID 962WaterHCID 8857Ethyl AcetateHCID 66838954ethyl(E)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylimidate dihydrochlorideHCID 670671765-Chloro-2-(4-fluorophenyl)-2-methoxyvaleric acid hydrazide monohydrochloride

生成物 1

HCID 670671618-(4-fluorophenyl)-8-methoxy-2-{(E)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]vinyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine収率 30.1%

試薬・触媒・溶媒 1

HCID 702Ethanol溶媒2 回

反応条件

温度
75 °C

実験手順

A solution of 5-chloro-2-(4-fluorophenyl)-2-methoxyvaleric acid hydrazide monohydrochloride (81 mg) and TEA (0.16 ml) in ethanol (1 ml) was added to a solution of ethyl (E)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylimidate dihydrochloride (94 mg) and TEA (0.16 ml) in ethanol (1 ml), and the reaction solution was stirred at 75° C. for 24 hours. The reaction solution was left to cool to room temperature. Then, ethyl acetate and water were added to the reaction solution, and the organic layer was separated. The organic layer washed with brine, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (carrier: Chromatorex™ NH; elution solvent: heptane-ethyl acetate system) and again purified by silica gel column chromatography (elution solvent: ethyl acetate-methanol system) to obtain 36 mg of 8-(4-fluorophenyl)-8-methoxy-2-{(E)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]vinyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine as a racemate. Then, the racemate was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm×25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 15 minutes and negative optical rotation (14.2 mg, 100% ee) and the title optically active compound with a retention time of 18 minutes and positive optical rotation (14.3 mg, >99% ee).

後処理

  1. waitThe reaction solution was left
  2. temperatureto cool to room temperature
  3. customthe organic layer was separated
  4. washThe organic layer washed with brine
  5. dry with materialdried over anhydrous magnesium sulfate
  6. concentrationconcentrated under reduced pressure
  7. customThe resulting residue was purified by silica gel column chromatography (carrier: Chromatorex™ NH; elution solvent: heptane-ethyl acetate system)
  8. customagain purified by silica gel column chromatography (elution solvent: ethyl acetate-methanol system)

出典と根拠

ORDレコード
ord-f409e810d43a45ecb7c9e3e2ec1f7f12
出典データセット
uspto-grants-2010_05
特許番号
US07713993B2

反応ノート

読み込み中…